These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 21550241)
1. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Orlikowski D; Pellegrini N; Prigent H; Laforêt P; Carlier R; Carlier P; Eymard B; Lofaso F; Annane D Neuromuscul Disord; 2011 Jul; 21(7):477-82. PubMed ID: 21550241 [TBL] [Abstract][Full Text] [Related]
2. 24-months results in two adults with Pompe disease on enzyme replacement therapy. Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117 [TBL] [Abstract][Full Text] [Related]
4. [Adult form of Pompe disease]. Ziółkowska-Graca B; Kania A; Zwolińska G; Nizankowska-Mogilnicka E Pneumonol Alergol Pol; 2008; 76(5):396-9. PubMed ID: 19003770 [TBL] [Abstract][Full Text] [Related]
5. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089 [TBL] [Abstract][Full Text] [Related]
6. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. Katzin LW; Amato AA J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427 [TBL] [Abstract][Full Text] [Related]
7. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258 [TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II. Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279 [TBL] [Abstract][Full Text] [Related]
9. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells. Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063 [TBL] [Abstract][Full Text] [Related]
10. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up. Andreassen CS; Schlütter JM; Vissing J; Andersen H Mol Genet Metab; 2014 May; 112(1):40-3. PubMed ID: 24685124 [TBL] [Abstract][Full Text] [Related]
11. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098 [TBL] [Abstract][Full Text] [Related]
12. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Mellies U; Lofaso F Respir Med; 2009 Apr; 103(4):477-84. PubMed ID: 19131232 [TBL] [Abstract][Full Text] [Related]
13. Pompe disease, the must-not-miss diagnosis: A report of 3 patients. Dubrovsky A; Corderi J; Karasarides T; Taratuto AL Muscle Nerve; 2013 Apr; 47(4):594-600. PubMed ID: 23463700 [TBL] [Abstract][Full Text] [Related]
14. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405 [TBL] [Abstract][Full Text] [Related]
15. [Enzyme replacement therapy in Pompe's disease]. Merk T; Wibmer T; Schumann C; Krüger S Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875 [TBL] [Abstract][Full Text] [Related]
17. [A retrospective study of six patients with late-onset Pompe disease]. Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925 [TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888 [TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Klinge L; Straub V; Neudorf U; Voit T Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317 [TBL] [Abstract][Full Text] [Related]
20. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Bernstein DL; Bialer MG; Mehta L; Desnick RJ Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]